BRAF and melanoma: In phase 3 clinical trials, the anti-PD-1 antibodies nivolumab [66] and pembrolizumab [67], respectively, demonstrated an improved OS compared to ipilimumab in advanced melanoma patients regardless of the BRAF mutation status and as a consequence constitute a front-line standard of care.